Companies

See how salaries can vary from company to company

Atossa Genetics Inc. a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions. It offers ForeCYTE Breast Aspirator... view company details

An international women's organization, Alpha Gamma Delta is committed to providing opportunities for personal development, service to others and the space for members to forge their own paths'all through a lifelong spirit of sisterhood. Alpha Gamma Delta believes in developing and encouraging members and staff to reach their full potential from the start. Members set out to contribute to the world's work in their communities, make lasting friendships and learn strong values in leadership and character. A company existing to provide opportunities for personal development through the spirit of s... view company details

Amber Charter Schools provide our students with an academically rigorous and well-rounded education, along with strong character development, enabling them to prosper in their future endeavors. Amber Charter Schools: -Ensure a rigorous and comprehensive core academic experience. -Support students in multiple ways. -Create an educational community that celebrates culture and fosters a love of learning. -Provide clear pathways to high school and college. Founded in 2000, Amber Charter Schools turns 20 in 2020! By 2025, the Amber Charter Schools network will serve almost 2000 students across thre... view company details

Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid drug that is in Phase 3 clinical trial for the treatment of systemic sclerosis and dermatomyositis, and in Phase 2 clinical trial to treat systemic lupus erythematosus and cystic fibrosis. The company also has a license to develop, manufacture, and market CRB-4001, a 2nd generation peripherally-restr... view company details

MRI Interventions, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging guidance. It offers ClearPoint system, a neuro-navigation system designed for placing catheters, electrodes, and laser fibers to treat various neurological diseases and conditions, as well as for performing biopsies. The company has a strategic agreement with Voyager Therapeutics, Inc. for the neurosurgical device servic... view company details

The City of Banning is a municipal corporation serving approximately 32,000 residents. The City is a full service City with police, parks, recreation, transit, streets, water, wastewater, electric, airport, fire, land use and zoning, and development services. Banning is strategically located in the San Gorgonio Pass area of Southern California along Interstate 10 between Los Angeles and Palm Springs. The community enjoys clean air, ample water supplies, and the inspiring vistas of the two tallest peaks in Southern California, Mt. San Jacinto and Mt. San Gorgonio. In addition, residents enjoy p... view company details

Renton is the center of opportunity where families and businesses thrive. The City has created an environment that supports business development while enhancing its quality of life. Community leaders nurture entrepreneurial sprit and foster successful partnerships. Bold economic development plans have diversified the City's employment base and strategically positioned Renton for the future. Renton is the fourth largest city in King County and the eight largest in Washington. On the south shore of Lake Washington, Renton's central location is at the heart of the vibrant Puget Sound region. Serv... view company details

D.R. Horton, Inc. operates as a homebuilding company in East, Midwest, Southeast, South Central, Southwest, and West regions in the United States. It engages in the acquisition and development of land; and construction and sale of homes in 27 states and 81 markets in the United States under the names of D.R. Horton, America's Builder, Express Homes, Emerald Homes, Freedom Homes, and Pacific Ridge Homes. The company constructs and sells single-family detached homes; and attached homes, such as town homes, duplexes, and triplexes. It is also involved in the origination and sale of mortgages; and... view company details

Celebrating Over 30 Years of Engineering Design Excellence: At DuBois Consultants, Inc. (DCI) we are committed to improving the communities in which we serve by providing design solutions tailored to meet our client's visions, while promoting a work environment dedicated to growth and professional development. Founded in 1988, DuBois Consultants Inc. is a CIVIL and STRUCTURAL consulting engineering firm that specializing in the study, design and construction of water facilities and infrastructures with offices in Wichita, Kansas and headquartered in Kansas City, Missouri. Our engineers provide... view company details

EastGroup Properties, Inc. is a self-administered equity real estate investment trust focused on the development, acquisition and operation of industrial properties in major Sunbelt markets throughout the United States with an emphasis in the states of Florida, Texas, Arizona, California and North Carolina. The Company's goal is to maximize shareholder value by being a leading provider in its markets of functional, flexible and quality business distribution space for location sensitive customers (primarily in the 15,000 to 70,000 square foot range). The Company's strategy for growth is based o... view company details

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. The company is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue ... view company details

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidate includes Emricasan, an orally active caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for portal hypertension; for liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function. The company is also developing CTS-2090, an orally active inhibitor of caspas... view company details

Hunt Midwest is a dynamic real estate development company privately held by the Lamar Hunt family. Based in Kansas City with over 50 years of development, construction and management experience, Hunt Midwest's wide range of projects include industrial, commercial, mission critical, self-storage, residential, multifamily, senior living, mixed use and SubTropolis, the world's largest underground business complex. Hunt Midwest is part of the Lamar Hunt family's diverse portfolio of entities involved in real estate, sports/media, energy/resources and private equity investments. In addition to Hunt... view company details

HedgePath Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for patients with cancers and non-cancerous proliferation disorders in the United States. It primarily focuses on the development of therapies for skin, lung, and prostate cancers. The company's Hedgehog signaling pathway is a primary regulator of cellular processes in vertebrates, including stem cell maintenance, cell differentiation, tissue polarity, and cell proliferation. It also develops super bioavailability (SUBA)-itraconazole oral capsules for patie... view company details

iBio, Inc., a biotechnology company, provides product development and manufacturing services to clients, collaborators, and third-party customers in the United States and internationally. The company's services cover the stages of product selection, regulatory approval, and commercial product launch. Its lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. It is also developing vaccine candidates for third parties. The company has collaboration agreements with ONEWAY Diagnostica; AzarGen Biotechnologies ... view company details

Jernigan Capital, Inc. is a New York Stock Exchange-listed real estate investment trust (NYSE: JCAP) that provides debt and equity capital to private developers, owners, and operators of self-storage facilities. Our mission is to be the preeminent capital partner for self-storage entrepreneurs nationwide by offering creative solutions through an experienced team demonstrating the highest levels of integrity, dedication, excellence and community, while maximizing shareholder value. The Jernigan Capital team has extensive experience in over 100 U.S. markets-from acquiring and managing self-stora... view company details

Lightbridge Corporation operates as a nuclear fuel technology company worldwide. It operates through two segments, Technology and Consulting. It offers all-metal fuel for operating and new build reactors; all-uranium seed and blanket fuel for existing plants and new build reactors; and thorium-based seed and blanket fuel for existing and new build reactors. The company also provides nuclear power consulting and strategic advisory services to commercial and governmental entities. Its services include integrated strategic advice across a range of areas, including regulatory development, nuclear ... view company details

Together we create value through places where communities thrive. Every day, people around the world live, work, shop, play or travel via an asset created by Lendlease. Lendlease is an international company with an Australian heritage, as well as local expertise across the core markets of Australia, Asia, the Americas and Europe. We have around 13,000 employees and more than 50,000 sub-contractors supporting the delivery of our active projects and managed assets around the world. Very few organisations can build cities from scratch, including the infrastructure to connect people, with skills t... view company details

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon biology and tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and r... view company details

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous). The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors... view company details